P/B
—
MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
$48M
Market Cap • 10/16/2026
2017
(9 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
48M
EV
39,2M
EV/Revenue
0
EV/EBITDA
-3,3
EV/EBIT
-3,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-39,5%
Total Yield
-39,5%
Payout
0%
Retained Earnings
-162,5M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
3,3%
% Goodwill
0%
ROE
57,9%
ROIC
98,7%
Growth
CAGR Op. Income 5Y
-5,7%
CAGR Net Income 5Y
-8,5%
CAGR EPS 5Y
-20,1%
CAGR OCF 5Y
-10,6%
Leverage
N.D./EBITDA
0,7
Debt/Equity
0%
Current Ratio
1,2
Quick Ratio
1,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!